Northern Africa and Western Asia vs Zambia: Percentage of bloodstream infection due to Escherichia coli resistant
Northern Africa and Western Asia
52.4%
in 2022
Zambia
76.5%
in 2022
Northern Africa and Western Asia rank
7th
Zambia rank
6th
Percentage of bloodstream infection due to Escherichia coli resistant over time
- Northern Africa and Western Asia
- Zambia
How they compare
Zambia currently reports 76.5% against 52.4% in Northern Africa and Western Asia, a difference of 24.1%.
That makes Zambia's figure about 1.5 times Northern Africa and Western Asia's.
Across all 6 years both countries report, Zambia has been ahead every year.
Northern Africa and Western Asia ranks 7th and Zambia ranks 6th of 16 groups.
Zambia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Northern Africa and Western Asia | Zambia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 46.1% | 58.9% | 12.8% | Zambia |
| 2020s | 53.7% | 88.4% | 34.7% | Zambia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher percentage of bloodstream infection due to escherichia coli resistant, Northern Africa and Western Asia or Zambia?
- Zambia, at 76.5% against 52.4% in Northern Africa and Western Asia as of 2022.
- What is the difference in percentage of bloodstream infection due to escherichia coli resistant between Northern Africa and Western Asia and Zambia?
- 24.1%, with Zambia ahead.
- How many years of comparable data are there for Northern Africa and Western Asia and Zambia?
- 6 years are reported by both, from 2016 to 2022.
- How do Northern Africa and Western Asia and Zambia rank globally for percentage of bloodstream infection due to escherichia coli resistant?
- Northern Africa and Western Asia ranks 7th and Zambia ranks 6th of 16 groups.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Percentage of bloodstream infection due to Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.